Allergy news and updates

autoimmune disorder eosinophilic esophagitis allergy milk calypso biotech

News and Trends 20 Feb 2019

Inflammatory Disease Treatment Backed by €20M Series A

The Swiss company Calypso Biotech has raised a sizeable €20M to fund its immunotherapy for an allergy-related inflammatory disease. The Series A round will help to develop Calypso’s antibody treatment for eosinophilic esophagitis, a condition where patients have an inflamed esophagus and difficulty swallowing. This condition is often linked with allergies to food, such as […]

February 20, 2019 - 2 minutesmins - By Jonathan Smith

desentum hay fever allergy vaccine espoo

Startup Scout 7 Dec 2018

This Hypoallergenic Vaccine Could Alleviate Hay Fever Faster Than Approved Vaccines

We decided to make a visit to Espoo, Finland, this week, to visit Desentum. The company is developing allergy vaccines that could be safer and faster than approved vaccines. Mission: To make a vaccine that decreases the time taken to reduce allergies compared with approved vaccines, which contain the natural allergen. Desentum plans to do […]

December 7, 2018 - 4 minutesmins - By Jonathan Smith

DBV Technologies Immunotherapy Milk Allergy

News and Trends 29 May 2018

This Immunotherapy Could Be The First to Treat Milk Allergy in Children

DBV Technologies has shown in a Phase II trial that its skin patch could desensitize over 60% of children with strong milk allergy. DBV Technologies, one of the largest public biotechs in France, is developing a skin patch technology to treat several forms of food allergies. The company has released new, promising data on its milk […]

May 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 May 2018

Positive House Dust Mite Immunotherapy Results for UK Biotech

British biotech Allergy Therapeutics reports positive early-stage results for its house dust mite immunotherapy. It’s been a good month for Allergy Therapeutics, which also reported positive Phase II results for its grass pollen allergy vaccine trial last week. It seems to be doing well, with a number of products targeting common allergies in late stage […]

May 29, 2018 - 1 minutemin - By Helen Albert

News and Trends 23 May 2018

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine. Roughly 30% of the population in Europe are allergic to grass pollen. The company plans […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 27 Feb 2018

DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial

DBV Technologies’ candidate could be the first treatment for allergies to cow milk after its Viaskin Milk skin patch achieved positive Phase II results. DBV Technologies is developing a skin patch, Viaskin, as an immunotherapy for the treatment peanut, egg, and milk allergies. In a Phase II study, Viaskin Milk has desensitized children between the […]

February 27, 2018 - 3 minutesmins - By Alex Dale

News and Trends 26 Feb 2018

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to develop immunotherapies against against grass pollen, peanut and house dust mite allergies. After raising €9.4M in January, ASIT Biotech has now brought the amount raised on the Euronext Brussels stock up to €13.9M. The funds will be put towards the Phase III […]

February 26, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 20 Nov 2017

After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy

DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45% last month after releasing Phase III data for ViaSkin Peanut, a treatment delivered via a skin patch aimed at reducing peanut allergy in children aged […]

November 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Oct 2017

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of a Phase III trial that was key to the approval of a treatment to reduce peanut allergy in children. After 12 months, 35% of children […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Sep 2017

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […]

September 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 2 Aug 2017

French Biotech May Save Toddlers from Life-Threatening Peanut Allergy

The first French biotech to NASDAQ, DBV, is expanding the patient group for its promising peanut allergy treatment to include toddlers. DBV Technologies’ Phase IIb results of its peanut allergy therapy, Viaskin Peanut, were one of 2016’s biggest clinical success stories when it successfully desensitized children to obviate life-threatening allergies. A trial in children between the ages […]

August 2, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 18 Apr 2017

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials in which the placebo beat its allergy immunotherapy. Circassia Pharmaceuticals has released the results from a Phase IIb trial for a house dust mite allergy immunotherapy. Although the treatment greatly reduced allergy symptoms in the patients, so did the placebo, making […]

April 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Allergy

Inflammatory Disease Treatment Backed by €20M Series A

This Hypoallergenic Vaccine Could Alleviate Hay Fever Faster Than Approved Vaccines

This Immunotherapy Could Be The First to Treat Milk Allergy in Children

Positive House Dust Mite Immunotherapy Results for UK Biotech

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

French Biotech May Save Toddlers from Life-Threatening Peanut Allergy

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!